Johnson & Johnson (NYSE:JNJ - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-six ratings firms that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $275.92.
Several research firms have commented on JNJ. Weiss Ratings lowered Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research note on Friday, October 23rd. Argus set a $300.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a report on Monday, August 3rd. Johnson Rice cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday, October 21st. Finally, Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the stock an "overweight" rating in a research note on Friday, October 16th.
Check Out Our Latest Report on Johnson & Johnson
Top Johnson & Johnson Stories
These are some of the JNJ stories that stood out recently:
- Positive Sentiment: J&J’s planned acquisition of Ollin Biosciences adds a Phase 3 candidate for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. The deal includes $2.2 billion upfront and up to about $1.1 billion in milestone payments; Blackstone is expected to provide $750 million toward development. UBS sees the asset as a potential growth driver beyond 2030. J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition UBS on Ollin as a Growth Driver
- Neutral Sentiment: The Ollin acquisition strengthens J&J’s ophthalmology portfolio, but its late-stage drug would enter a competitive market and still faces clinical and commercial execution risks. J&J Bets $2.2B on Ollin’s Vision Loss Drug
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to its talc baby powder, adding to ongoing litigation concerns. Separately, Pomerantz LLP said it is investigating claims on behalf of J&J investors; an investigation is not a finding of wrongdoing, but may add uncertainty. Louisiana Appeals Court Upholds Damages in Mesothelioma Case Pomerantz Investor Alert
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $278.42 on Wednesday. The firm has a market cap of $670.23 billion, a PE ratio of 42.18, a PEG ratio of 2.79 and a beta of 0.22. The firm has a fifty day moving average of $267.31 and a 200 day moving average of $250.38. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a one year low of $198.53 and a one year high of $290.25.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm's revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is currently 81.21%.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the business's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Johnson & Johnson
A number of institutional investors have recently added to or reduced their stakes in JNJ. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $28,000. Matrix Trust Co grew its holdings in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after buying an additional 54 shares in the last quarter. Navigoe LLC grew its holdings in Johnson & Johnson by 60.4% in the 3rd quarter. Navigoe LLC now owns 146 shares of the company's stock worth $38,000 after buying an additional 55 shares in the last quarter. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company's stock.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.